Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma

Table 1

Benralizumab: summary of the main phase 3 clinical trials.

Authors and trial name	Duration	Number of patients	Main results
Bleecker et al. (2016) [23], SIROCCO	48 weeks	1205	Fewer asthma exacerbations, higher FEV1
FitzGerald et al. (2016) [24], CALIMA	56 weeks	1306	Fewer asthma exacerbations, higher FEV1
Nair et al. (2017) [25], ZONDA	28 weeks	220	Lower intake of oral corticosteroids, fewer asthma exacerbations
Ferguson et al. (2017) [26], BISE	12 weeks	211	Smaller numbers of blood eosinophils